Change From Baseline in BPI-SF (Brief-Pain Inventory - Short Form) Pain Interference Scale
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer · Source last updated 2025-01-13
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
MEAN
Unit
Score on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline (BL), Cycle 2 to Cycle 13 (Week 1 Day 1), End of Treatment (EoT) (cycle duration for Cycle 1-6 = 6 weeks and for Cycle 7 and beyond = 12 weeks)
What was measured
The BPI-SF is a generic pain assessment tool used in research and practice for pain assessment in musculoskeletal conditions. The higher the BPI-SF score, the worse the pain. The BPI-SF consists of 4 questions regarding pain intensity (worst pain intensity, least pain intensity, average pain intensity and pain right now), 2 questions on the use of analgesics, and 7 questions on how the level pain has interfered with the subject's life (General Activity, Mood, Walking Ability, Normal Work, Relations with other people, Sleep, Enjoyment of Life). Interference items consist of scores from 0 ("Does Not Interfere") to 10 ("Completely Interferes"). BPI-SF Interference scale is the mean of non-missing items of the 7 items on pain interference, if there are 4 or more items not missing; otherwise this scale is set to missing.
Analysis population: PFS Full Analysis Set (PFS-FAS). Only participants with non-missing score both at Baseline and at post-baseline visits were included in the analysis.
Groups in this outcome
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
385
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
196
Reported measurements
Cycle 2, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
311
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
100
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
-0.40
2.167
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
0.58
2.700
Not reported
Not reported
Not reported
Cycle 3, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
274
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
52
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
-0.35
2.348
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
-0.15
2.216
Not reported
Not reported
Not reported
Cycle 4, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
223
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
32
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
-0.33
2.249
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
0.21
2.762
Not reported
Not reported
Not reported
Cycle 5, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
183
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
21
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
-0.32
2.223
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
0.52
3.480
Not reported
Not reported
Not reported
Cycle 6, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
161
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
13
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
-0.28
2.166
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
0.49
3.354
Not reported
Not reported
Not reported
Cycle 7, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
122
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
11
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
-0.22
1.882
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
0.06
2.570
Not reported
Not reported
Not reported
Cycle 8, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
86
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
5
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
0.18
1.926
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
-0.26
1.291
Not reported
Not reported
Not reported
Cycle 9, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
55
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
6
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
-0.15
1.751
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
0.12
1.667
Not reported
Not reported
Not reported
Cycle 10, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
33
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
2
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
0.62
2.141
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
1.50
1.313
Not reported
Not reported
Not reported
Cycle 11, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
12
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
2
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
-0.06
1.334
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
0.36
4.748
Not reported
Not reported
Not reported
Cycle 12, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
4
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
0
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
-0.89
0.914
Not reported
Not reported
Not reported
Cycle 13, Week 1, Day 1 change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
1
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
0
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
-0.43
NA
Not reported
Not reported
NA: Only one participant analyzed
End of Treatment (EoT) change from BL
Analysis denominator · Participants
Group
Source count
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
165
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
88
Values in Score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
0.73
2.756
Not reported
Not reported
Not reported
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
0.29
2.385
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
spread
2.167
value
-0.40
group Id
OG001
spread
2.700
value
0.58
denoms
counts
group Id
OG000
value
311
group Id
OG001
value
100
units
Participants
title
Cycle 2, Week 1, Day 1 change from BL
categories
measurements
group Id
OG000
spread
2.348
value
-0.35
group Id
OG001
spread
2.216
value
-0.15
denoms
counts
group Id
OG000
value
274
group Id
OG001
value
52
units
Participants
title
Cycle 3, Week 1, Day 1 change from BL
categories
measurements
group Id
OG000
spread
2.249
value
-0.33
group Id
OG001
spread
2.762
value
0.21
denoms
counts
group Id
OG000
value
223
group Id
OG001
value
32
units
Participants
title
Cycle 4, Week 1, Day 1 change from BL
categories
measurements
group Id
OG000
spread
2.223
value
-0.32
group Id
OG001
spread
3.480
value
0.52
denoms
counts
group Id
OG000
value
183
group Id
OG001
value
21
units
Participants
title
Cycle 5, Week 1, Day 1 change from BL
categories
measurements
group Id
OG000
spread
2.166
value
-0.28
group Id
OG001
spread
3.354
value
0.49
denoms
counts
group Id
OG000
value
161
group Id
OG001
value
13
units
Participants
title
Cycle 6, Week 1, Day 1 change from BL
categories
measurements
group Id
OG000
spread
1.882
value
-0.22
group Id
OG001
spread
2.570
value
0.06
denoms
counts
group Id
OG000
value
122
group Id
OG001
value
11
units
Participants
title
Cycle 7, Week 1, Day 1 change from BL
categories
measurements
group Id
OG000
spread
1.926
value
0.18
group Id
OG001
spread
1.291
value
-0.26
denoms
counts
group Id
OG000
value
86
group Id
OG001
value
5
units
Participants
title
Cycle 8, Week 1, Day 1 change from BL
categories
measurements
group Id
OG000
spread
1.751
value
-0.15
group Id
OG001
spread
1.667
value
0.12
denoms
counts
group Id
OG000
value
55
group Id
OG001
value
6
units
Participants
title
Cycle 9, Week 1, Day 1 change from BL
categories
measurements
group Id
OG000
spread
2.141
value
0.62
group Id
OG001
spread
1.313
value
1.50
denoms
counts
group Id
OG000
value
33
group Id
OG001
value
2
units
Participants
title
Cycle 10, Week 1, Day 1 change from BL
categories
measurements
group Id
OG000
spread
1.334
value
-0.06
group Id
OG001
spread
4.748
value
0.36
denoms
counts
group Id
OG000
value
12
group Id
OG001
value
2
units
Participants
title
Cycle 11, Week 1, Day 1 change from BL
categories
measurements
group Id
OG000
spread
0.914
value
-0.89
denoms
counts
group Id
OG000
value
4
group Id
OG001
value
0
units
Participants
title
Cycle 12, Week 1, Day 1 change from BL
categories
measurements
comment
NA: Only one participant analyzed
group Id
OG000
spread
NA
value
-0.43
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
0
units
Participants
title
Cycle 13, Week 1, Day 1 change from BL
denoms
counts
group Id
OG000
value
385
group Id
OG001
value
196
units
Participants
description
The BPI-SF is a generic pain assessment tool used in research and practice for pain assessment in musculoskeletal conditions. The higher the BPI-SF score, the worse the pain. The BPI-SF consists of 4 questions regarding pain intensity (worst pain intensity, least pain intensity, average pain intensity and pain right now), 2 questions on the use of analgesics, and 7 questions on how the level pain has interfered with the subject's life (General Activity, Mood, Walking Ability, Normal Work, Relations with other people, Sleep, Enjoyment of Life). Interference items consist of scores from 0 ("Does Not Interfere") to 10 ("Completely Interferes"). BPI-SF Interference scale is the mean of non-missing items of the 7 items on pain interference, if there are 4 or more items not missing; otherwise this scale is set to missing.
dispersion Type
Standard Deviation
groups
description
Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used
id
OG000
title
Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)
description
Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator
id
OG001
title
Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone
param Type
MEAN
population Description
PFS Full Analysis Set (PFS-FAS). Only participants with non-missing score both at Baseline and at post-baseline visits were included in the analysis.
reporting Status
POSTED
time Frame
Baseline (BL), Cycle 2 to Cycle 13 (Week 1 Day 1), End of Treatment (EoT) (cycle duration for Cycle 1-6 = 6 weeks and for Cycle 7 and beyond = 12 weeks)
title
Change From Baseline in BPI-SF (Brief-Pain Inventory - Short Form) Pain Interference Scale